COBACTAN LA 7.5% suspension for injection for cattle
Country: Hungary
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
22-03-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
cefquinome sulfate 75 mg/ml
Available from:
Intervet
ATC code:
QJ01DE90
Pharmaceutical form:
Suspension for injection
Therapeutic group:
Cefquinome
Therapeutic area:
Cattle
Authorization date:
2011-03-11
Summary of Product characteristics
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
COBACTAN LA 7.5% w/v suspension for injection for cattle
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance:
Cefquinome (as sulfate)
75 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection
White to off-white resuspendable suspension
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bovine respiratory disease (BRD) associated with _Mannheimia haemolytica, _
_Pasteurella multocida and Histophilus somni_ sensitive to cefquinome._ _
4.3
CONTRAINDICATIONS
Do not use in animals which are known to be hypersensitive to cephalosporin antibiotics and other
β-lactam antibiotics.
Do not use in poultry (including eggs) due to risk of spread of antimicrobial resistance to humans.
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Cobactan 7.5% selects for resistant strains such as bacteria carrying extended spectrum
betalactamases (ESBL) which may constitute a risk to human health if these strains disseminate to
humans e.g. via food. For this reason, Cobactan 7.5% should be reserved for the treatment of clinica l
conditions which have responded poorly, or are expected to respond poorly (refers to very acute cases
when treatment must be initiated without bacteriological diagnosis), to first line treatment. Official,
national and regional antimicrobial policies should be taken into account when the product is used.
Increased use, including use of the product deviating from the instructi
Read the complete document
